INVENTIVA SA (IVA.PA) Stock Fundamental Analysis
EPA:IVA - FR0013233012 - Common Stock
4.8 EUR
+0.3 (+6.67%)
Overall IVA gets a fundamental rating of 1 out of 10. We evaluated IVA against 74 industry peers in the Biotechnology industry. Both the profitability and financial health of IVA have multiple concerns. IVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IVA had negative earnings in the past year.
In the past year IVA has reported a negative cash flow from operations.
In the past 5 years IVA always reported negative net income.
IVA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -154.84%, IVA is doing worse than 81.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -154.84% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IVA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IVA has been increased compared to 1 year ago.
The number of shares outstanding for IVA has been increased compared to 5 years ago.
The debt/assets ratio for IVA has been reduced compared to a year ago.
2.2 Solvency
IVA has an Altman-Z score of -5.21. This is a bad value and indicates that IVA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.21, IVA is not doing good in the industry: 71.62% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.21 |
ROIC/WACCN/A
WACC7.59%
2.3 Liquidity
A Current Ratio of 0.92 indicates that IVA may have some problems paying its short term obligations.
IVA has a worse Current ratio (0.92) than 74.32% of its industry peers.
A Quick Ratio of 0.92 indicates that IVA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.92, IVA is doing worse than 74.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.92 | ||
| Quick Ratio | 0.92 |
3. Growth
3.1 Past
IVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.47%.
Looking at the last year, IVA shows a very negative growth in Revenue. The Revenue has decreased by -47.37% in the last year.
Measured over the past years, IVA shows a small growth in Revenue. The Revenue has been growing by 5.62% on average per year.
EPS 1Y (TTM)-20.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.47%
Revenue 1Y (TTM)-47.37%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%-41.21%
3.2 Future
IVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.89% yearly.
Based on estimates for the next years, IVA will show a very strong growth in Revenue. The Revenue will grow by 115.67% on average per year.
EPS Next Y63.99%
EPS Next 2Y28.86%
EPS Next 3Y15.31%
EPS Next 5Y20.89%
Revenue Next Year266.89%
Revenue Next 2Y90.91%
Revenue Next 3Y56.69%
Revenue Next 5Y115.67%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IVA's earnings are expected to grow with 15.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.86%
EPS Next 3Y15.31%
5. Dividend
5.1 Amount
No dividends for IVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:IVA (9/3/2025, 4:01:30 PM)
4.8
+0.3 (+6.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners54.98%
Inst Owner ChangeN/A
Ins Owners6.82%
Ins Owner ChangeN/A
Market Cap667.60M
Analysts86.67
Price Target8.09 (68.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.07%
PT rev (3m)-10.07%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)18.09%
EPS NY rev (3m)18.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)25.05%
Revenue NY rev (3m)56.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 72.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.94
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.07
BVpS-0.77
TBVpS-0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -154.84% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 6.41% | ||
| Cap/Sales | 3.62% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.92 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z | -5.21 |
F-Score3
WACC7.59%
ROIC/WACCN/A
Cap/Depr(3y)20.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.77%
Cap/Sales(5y)20.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.47%
EPS Next Y63.99%
EPS Next 2Y28.86%
EPS Next 3Y15.31%
EPS Next 5Y20.89%
Revenue 1Y (TTM)-47.37%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%-41.21%
Revenue Next Year266.89%
Revenue Next 2Y90.91%
Revenue Next 3Y56.69%
Revenue Next 5Y115.67%
EBIT growth 1Y6.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.98%
EBIT Next 3Y19.35%
EBIT Next 5Y21.43%
FCF growth 1Y-5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.29%
OCF growth 3YN/A
OCF growth 5YN/A